SUNNYVALE, Calif., April 25, 2025 /PRNewswire/ - Willow Biosciences Inc. ("Willow" or the "Company") (TSX: WLLW) (OTCQB: CANSF) is pleased to announce the voting results from its annual general and special meeting of shareholders held on April 25, 2025 (the "Meeting"). A total of 59,214,893 common shares, representing approximately 40.88% of the Company's issued and outstanding shares were represented at the meeting.
The shareholders approved the setting of the number of directors of Willow at 5 directors, and the following nominees were elected as directors of Willow for the ensuing year with the specific voting results being as follows:
Votes For | Votes Withheld | |||
Director | # | % | # | % |
Dr. Chris Savile | 46,902,346 | 88.3 % | 6,234,676 | 11.7 % |
Dr. Jim Lalonde | 46,965,380 | 88.4 % | 6,171,642 | 11.6 % |
Donald Archibald | 44,900,287 | 84.5 % | 8,236,735 | 15.5 % |
Raffi Asadorian | 46,963,057 | 88.4 % | 6,173,965 | 11.6 % |
Al Foreman | 46,900,723 | 88.3 % | 6,236,299 | 11.7 % |
In addition, shareholders approved the below matters. The resolutions approving the below matters may be viewed in full in the Company's management information circular dated March 26, 2025 (the "Information Circular").
Votes For | ||
Director | # | % |
Appointment of KPMG LLP as the Company's auditor for the ensuring year | 51,882,364 | 87.6 % |
The proposed sale of the shares of Epimeron USA, Inc., the Corporation's | 46,996,397 | 88.4 % |
To authorize the Corporation's board of directors, at its sole discretion, to | 48,853,362 | 82.5 % |
For complete voting results on all matters approved at the Meeting, please see the Company's Report of Voting Results dated April 25, 2025, available on SEDAR+ at www.sedarplus.ca.
About Willow Biosciences Inc.
Willow develops and produces precision fermented functional ingredients for the health and wellness, food and beverage and personal care markets. Willow's FutureGrownTM biotechnology platform allows large-scale production with sustainability at its core. Willow's R&D team has a proven track record of developing and commercializing bio-based manufacturing processes and products to benefit our B2B partners and their customers.
For more information, visit www.willowbio.com or contact:
Travis Doupe
Chief Financial Officer
E: [email protected]
SOURCE Willow Biosciences Inc.
